Initial general form for registration of a class of securities pursuant to Section 12(g)

Condensed Consolidated Balance Sheets

v3.22.2.2
Condensed Consolidated Balance Sheets - USD ($)
Jun. 30, 2022
Dec. 31, 2021
Dec. 31, 2020
Current assets:      
Cash $ 6,598 $ 46 $ 31,294
Accounts receivable, net (including related party receivable of $12,327 and $21,852 at June 30, 2022 and December 31, 2021, respectively) 52,837 32,800 151,363
Prepaid expenses and other current assets 7,718 1,717
Total current assets 67,153 32,846 184,374
Property and equipment, net 685
Total assets 67,153 32,846 185,059
Current liabilities:      
Accounts payable 1,053,375 937,698 726,220
Accrued expenses 1,437,870 1,446,722 1,308,283
Due to Former Parent 803,416 374,473
Current portion of notes payable 223,952 134,153 134,118
Total current liabilities 3,518,613 2,893,046 2,168,621
Notes payable – Long term 60,401 60,401 103,900
Total liabilities 12,802,660 12,161,843 2,272,521
Commitments and contingencies  
Stockholders’ Deficit      
Preferred Series A Stock, Par Value $0.0001, 1,000 shares authorized, 1,000 shares issued and outstanding at June 30, 2022 and December 31, 2021
Common Stock, Par Value $0.0001, 325,000,000 shares authorized, 234,953,286 shares issued and outstanding at June 30, 2022 and December 31, 2021 23,495 23,495
Additional Paid-In Capital 5,857,658 5,857,658
Accumulated Deficit (18,616,660) (18,010,150)
Parent’s net investment deficit in Advanced Molecular and Health Technology Solutions Group   (2,087,462)
Total Stockholders’ Deficit (12,735,507) (12,128,997) (2,087,462)
Total Liabilities and Stockholders’ Deficit 67,153 32,846 185,059
Series B Preferred Stock [Member]      
Current liabilities:      
 Total temporary capital 9,086,396 9,086,396
Series C Preferred Stock [Member]      
Current liabilities:      
 Total temporary capital $ 137,250 $ 122,000